Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Merck & Co. Inc. MRK inched 0.08% higher to $99.45 Tuesday, on what proved to be an all-around favorable trading ...

We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a ...

Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

A Fremont pharmaceutical company received an investment of approximately $50 million — about $3.56 per share — in a private ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of ...

On Thursday, Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials ...

On Friday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.05 which represents a decrease of $-1.47 or -1.48% from the prior close of $99.52. The stock opened at $98.83 and touched a ...

A Fremont pharmaceutical company received an investment of approximately $50 million in a private placement from Merck & Co.